In vitro activities of BAL9141, a novel broad-spectrum pyrrolidinone cephalosporin, against gram-negative nonfermenters

R Zbinden; V Pünter; A von Graevenitz

doi:10.1128/AAC.46.3.872-875.2002

In vitro activities of BAL9141, a novel broad-spectrum pyrrolidinone cephalosporin, against gram-negative nonfermenters

Antimicrob Agents Chemother. 2002 Mar;46(3):871-4. doi: 10.1128/AAC.46.3.872-875.2002.

Authors

R Zbinden¹, V Pünter, A von Graevenitz

Affiliation

¹ Department of Medical Microbiology, University of Zurich, 8028 Zurich, Switzerland. RZbinden@immv.unizh.ch

Abstract

The activities of BAL9141 (formerly Ro 63-9141), a novel pyrrolidinone-3-ylidenemethyl cephalosporin, against 244 strains of gram-negative nonfermenters were evaluated. The overall MIC at which 50% of isolates are inhibited (MIC50) and the overall MIC90 were 2 and 64 microg/ml, respectively, which are similar to those of imipenem, lower than those of the other cephalosporins tested, amoxicillin, and the ticarcillin-clavulanic acid combination, and much higher than those of ciprofloxacin. BAL9141 shows species-dependent activity in vitro against a variety of gram-negative nonfermentative pathogens.

Publication types

Comparative Study
Research Support, Non-U.S. Gov't

MeSH terms

Cephalosporins / pharmacology*
Fermentation
Glucose / metabolism
Gram-Negative Bacteria / drug effects*
Microbial Sensitivity Tests

Substances

Cephalosporins
ceftobiprole
Glucose